Connor, Clark & Lunn Investment Management (CC&L)’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $11.9K | Sell |
|
|||||
|
2024
Q4 | $93.4K | Sell |
|
|||||
|
2024
Q3 | $173K | Sell |
|
|||||
|
2024
Q2 | $207K | Buy |
|
|||||
|
2024
Q1 | $305K | Buy |
|
|||||
|
2023
Q4 | $177K | Sell |
|
|||||
|
2023
Q3 | $215K | Sell |
|
|||||
|
2023
Q2 | $357K | Buy |
|
|||||
|
2023
Q1 | $362K | Sell |
|
|||||
|
2022
Q4 | $306K | Sell |
|
|||||
|
2022
Q3 | $326K | Buy |
|
|||||
|
2022
Q2 | $214K | Buy |
|
|||||
|
2022
Q1 | $18K | Buy |
|
|||||
|
2020
Q4 | – | Sell |
|
|||||
|
2020
Q3 | $14K | Sell |
|
|||||
|
2020
Q2 | $49K | Buy |
|
|||||
|
2020
Q1 | $42K | Buy |
|
|||||
|
2019
Q4 | $20K | Buy |
|
|||||
|
2019
Q2 | – | Sell |
|
|||||
|
2019
Q1 | $18K | Buy |
|
|||||
|
2018
Q1 | – | Sell |
|
|||||
|
2017
Q4 | $210K | Sell |
|
|||||
|
2017
Q3 | $309K | Buy |
|
|||||
|
2017
Q2 | $316K | Buy |
|
|||||
|
2017
Q1 | $67K | Buy |
|